Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable ...
The approval broadens Vetmedin’s label, which already covers management of mild to severe congestive heart failure in dogs with clinical myxomatous mitral valve disease or dilated cardiomyopathy.
A novel approach to removing excess fluid through the skin and a new strategy to prevent right ventricular failure after LVAD implantation are among the highlights of the January issue of the Journal ...
The MarketWatch News Department was not involved in the creation of this content.-- Heart disease affects approximately 10 percent of dogs in their lifetime1 -- VETMEDIN(R) (pimob ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results